NCT00110071View on ClinicalTrials.gov

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2011

Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia
Interventions
DRUG

fludarabine phosphate

Given IV

PROCEDURE

peripheral blood stem cell transplantation

Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)

RADIATION

iodine I 131 tositumomab

Given IV (dosimetric dose) or via central line (therapeutic dose)

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

flow cytometry

Correlative studies

GENETIC

polymerase chain reaction

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00110071 - Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter